CLPT — Clearpoint Neuro Cashflow Statement
0.000.00%
- $430.16m
- $421.14m
- $31.39m
Annual cashflow statement for Clearpoint Neuro, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.78 | -14.4 | -16.4 | -22.1 | -18.9 |
| Depreciation | |||||
| Non-Cash Items | 1.3 | 3.24 | 4.31 | 8.1 | 7.58 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.66 | -1.68 | -4.29 | -0.356 | 1.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.81 | -12.7 | -16.2 | -13.7 | -8.95 |
| Capital Expenditures | -0.482 | -0.168 | -1.15 | -1.05 | -0.275 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -9.59 | 10 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.482 | -0.168 | -10.7 | 8.95 | -0.275 |
| Financing Cash Flow Items | — | -0.599 | -0.336 | -0.21 | -0.424 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 22.7 | 46.9 | 0.409 | 0.296 | 6.19 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.4 | 34 | -26.5 | -4.47 | -3.04 |